Luis E. Raez, MD, of Miami Cancer Institute, reports that with extended COPERNICUS follow-up, rash in the first 4 months of subcutaneous amivantamab plus lazertinib was lower than in MARIPOSA, similar ...
Delhivery delivered strong Q2 FY26 results, with revenue from services up 16% YoY to INR 2,546 crore and EBITDA more than doubling YoY to INR 150 crore (5.9% margin). Express parcel volumes surged ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results